TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThe updated food pyramid, a cornerstone of public health nutrition advice, has emerged amid criticism regarding opaque scientific practices and the influence of industry funding on the scientific panel responsible for its creation. This post unpacks the challenges and pressures faced during the guideline development process.
TCB TeamJan 17, 2026
Regulatory & PolicyRotavirus, a leading cause of severe diarrhea in young children, was once broadly prevented through universal vaccination programs. However, recent changes in vaccine recommendations have sparked debate among experts concerning public health outcomes and preventable disease burdens.
TCB TeamJan 17, 2026
Biopharmaceutical IndustryPregnant individuals have often faced uncertainty regarding the safety of acetaminophen (Tylenol), one of the most commonly used medications during pregnancy. The latest findings provide reassurance by clarifying that its use is not associated with increased risk of neurodevelopmental disorders in offspring.
TCB TeamJan 17, 2026
Regulatory & PolicyRecent data from South Carolina's state health officials reveal a nearly 30% increase in reported measles cases over the last few days, reaching more than 550 cases. This resurgence poses critical questions about vaccination coverage, outbreak containment, and healthcare system preparedness.
TCB TeamJan 16, 2026
Biopharmaceutical IndustryIn a move to streamline operations and concentrate resources, Vedanta Biosciences, a Cambridge-based biotech company, recently laid off half of its workforce and furloughed many others. This restructuring aims to prioritize the upcoming Phase III study of its lead candidate targeting C. difficile infections.
TCB TeamJan 16, 2026
Biopharmaceutical IndustryMarket rumors suggest that Sanofi may be looking to acquire Ocular Therapeutix, whose lead drug candidate, Axpaxli, targets wet age-related macular degeneration. The ongoing Phase III trial results expected this quarter could be pivotal for the company’s future and the takeover possibilities.
TCB TeamJan 16, 2026
Healthcare InvestmentWith a substantial fund allocation, the Novo Nordisk Foundation aims to accelerate breakthrough innovations, fostering a sustainable ecosystem for biotechnology and health-related technological advances in both Denmark and the wider European landscape.
TCB TeamJan 16, 2026
Medical TechnologyNoninvasive diagnostic devices for liver conditions are gaining prominence due to their ability to provide clinical insights without the need for invasive procedures. This guide explores how these technologies work and profiles leading organizations developing these solutions.
TCB TeamJan 16, 2026
Biopharmaceutical IndustryBispecific antibodies, which simultaneously target two different antigens, are capturing significant interest within cancer research and pharmaceutical dealmaking. Takeda’s strategic deal reflects both the promising clinical potential and the commercial value attributed to this innovative class of therapeutics.
TCB TeamJan 16, 2026
Regulatory & PolicyThe settlement marks one of the largest risk-adjustment settlements in recent history, underscoring ongoing federal scrutiny of Medicare Advantage programs. This case highlights the complexities and regulatory challenges facing healthcare organizations operating within government programs.
TCB TeamJan 16, 2026
Biopharmaceutical IndustryDay 4 of the J.P. Morgan Healthcare Conference featured in-depth discussions with Regeneron’s chief scientist George Yancopoulos, market forecasts for biotech IPOs, and close attention on Johnson & Johnson’s strategic moves.
TCB TeamJan 15, 2026
Regulatory & PolicyJazz Pharmaceuticals recently sold one of its Priority Review Vouchers (PRVs) for $200 million, marking a substantial financial transaction as the future of the PRV program hangs in the balance due to legislative delays. The details of the buyer remain undisclosed, and the allocation of the remaining proceeds is unclear, emphasizing the nuanced complexities in biotech regulatory incentives.
TCB TeamJan 15, 2026